Effects of Colchicine on Atherosclerotic Plaque Stabilization: a Multimodality Imaging Study in an Animal Model.


Journal

Journal of cardiovascular translational research
ISSN: 1937-5395
Titre abrégé: J Cardiovasc Transl Res
Pays: United States
ID NLM: 101468585

Informations de publication

Date de publication:
02 2021
Historique:
received: 11 08 2019
accepted: 14 02 2020
pubmed: 7 3 2020
medline: 27 11 2021
entrez: 7 3 2020
Statut: ppublish

Résumé

Colchicine demonstrated clinical benefits in the treatment of stable coronary artery disease. Our aim was to evaluate the effects of colchicine on atherosclerotic plaque stabilization. Atherosclerosis was induced in the abdominal aorta of 20 rabbits with high-cholesterol diet and balloon endothelial denudation. Rabbits were randomized to receive either colchicine or placebo. All animals underwent MRI,

Identifiants

pubmed: 32140929
doi: 10.1007/s12265-020-09974-7
pii: 10.1007/s12265-020-09974-7
doi:

Substances chimiques

Gout Suppressants 0
Colchicine SML2Y3J35T

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

150-160

Références

Tousoulis, D., et al. (2016). Inflammatory cytokines in atherosclerosis: current therapeutic approaches. European Heart Journal, 37(22), 1723–1732.
pubmed: 26843277
Libby, P. (2012). Inflammation in atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 32(9), 2045–2051.
pubmed: 22895665 pmcid: 3422754
Naruko, T., et al. (2002). Neutrophil infiltration of culprit lesions in acute coronary syndromes. Circulation, 106(23), 2894–2900.
pubmed: 12460868
Vacek, T. P., et al. (2015). Matrix metalloproteinases in atherosclerosis: role of nitric oxide, hydrogen sulfide, homocysteine, and polymorphisms. Vascular Health and Risk Management, 11, 173–183.
pubmed: 25767394 pmcid: 4354431
Peters, M. J., et al. (2009). Does rheumatoid arthritis equal diabetes mellitus as an independent risk factor for cardiovascular disease? A prospective study. Arthritis and Rheumatism, 61(11), 1571–1579.
pubmed: 19877093
Ridker, P. M. (2014). Inflammation, C-reactive protein, and cardiovascular disease: moving past the marker versus mediator debate. Circulation Research, 114(4), 594–595.
pubmed: 24526672
Moreno, P. R., & Kini, A. (2012). Resolution of inflammation, statins, and plaque regression. JACC: Cardiovascular Imaging, 5(2), 178–181.
pubmed: 22340824
Ridker, P. M., et al. (2017). Antiinflammatory therapy with canakinumab for atherosclerotic disease. The New England Journal of Medicine, 377(12), 1119–1131.
pubmed: 28845751
Ridker, P. M., et al. (2019). Low-dose methotrexate for the prevention of atherosclerotic events. The New England Journal of Medicine, 380(8), 752–762.
pubmed: 30415610
Pan, W., et al. (2019). Immunomodulation by exosomes in myocardial infarction. Journal of Cardiovascular Translational Research, 12(1), 28–36.
pubmed: 30374796
Leung, Y. Y., Yao Hui, L. L., & Kraus, V. B. (2015). Colchicine—update on mechanisms of action and therapeutic uses. Seminars in Arthritis and Rheumatism, 45(3), 341–350.
pubmed: 26228647 pmcid: 4656054
Crittenden, D. B., et al. (2012). Colchicine use is associated with decreased prevalence of myocardial infarction in patients with gout. The Journal of Rheumatology, 39(7), 1458–1464.
pubmed: 22660810 pmcid: 3733459
Langevitz, P., et al. (2001). Prevalence of ischemic heart disease in patients with familial Mediterranean fever. The Israel Medical Association Journal, 3(1), 9–12.
pubmed: 11344818
Nidorf, S. M., et al. (2013). Low-dose colchicine for secondary prevention of cardiovascular disease. Journal of the American College of Cardiology, 61(4), 404–410.
pubmed: 23265346
Nidorf, S. M., et al. (2019). The effect of low-dose colchicine in patients with stable coronary artery disease: the LoDoCo2 trial rationale, design, and baseline characteristics. American Heart Journal, 218, 46–56.
pubmed: 31706144
Deftereos, S., et al. (2013). Colchicine treatment for the prevention of bare-metal stent restenosis in diabetic patients. Journal of the American College of Cardiology, 61(16), 1679–1685.
pubmed: 23500260
Tardif, J. C., et al. (2019). Efficacy and safety of low-dose colchicine after myocardial infarction. The New England Journal of Medicine, 381(26), 2497–2505.
pubmed: 31733140
Bhattacharyya, B., et al. (2008). Anti-mitotic activity of colchicine and the structural basis for its interaction with tubulin. Medicinal Research Reviews, 28(1), 155–183.
pubmed: 17464966
Ganguly, A., et al. (2013). Microtubule dynamics control tail retraction in migrating vascular endothelial cells. Molecular Cancer Therapeutics, 12(12), 2837–2846.
pubmed: 24107446 pmcid: 4011668
Paschke, S., et al. (2013). Technical advance: inhibition of neutrophil chemotaxis by colchicine is modulated through viscoelastic properties of subcellular compartments. Journal of Leukocyte Biology, 94(5), 1091–1096.
pubmed: 23901122
Peachman, K. K., et al. (2004). Functional microtubules are required for antigen processing by macrophages and dendritic cells. Immunology Letters, 95(1), 13–24.
pubmed: 15325793
Sullivan, D. P., & Muller, W. A. (2014). Neutrophil and monocyte recruitment by PECAM, CD99, and other molecules via the LBRC. Seminars in Immunopathology, 36(2), 193–209.
pubmed: 24337626
Martinon, F., et al. (2006). Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature, 440(7081), 237–241.
pubmed: 16407889 pmcid: 16407889
Pope, R. M., & Tschopp, J. (2007). The role of interleukin-1 and the inflammasome in gout: implications for therapy. Arthritis and Rheumatism, 56(10), 3183–3188.
pubmed: 17907163
Cimmino, G., et al. (2018). Colchicine reduces platelet aggregation by modulating cytoskeleton rearrangement via inhibition of cofilin and LIM domain kinase 1. Vascular Pharmacology, 111, 62–70.
pubmed: 30287213
Phinikaridou, A., et al. (2009). A robust rabbit model of human atherosclerosis and atherothrombosis. Journal of Lipid Research, 50(5), 787–797.
pubmed: 19141434 pmcid: 2666165
Phinikaridou, A., et al. (2010). In vivo detection of vulnerable atherosclerotic plaque by MRI in a rabbit model. Circulation. Cardiovascular Imaging, 3(3), 323–332.
pubmed: 20194634
Schroeder, S., et al. (2001). Noninvasive detection and evaluation of atherosclerotic coronary plaques with multislice computed tomography. Journal of the American College of Cardiology, 37(5), 1430–1435.
pubmed: 11300457
Yla-Herttuala, S., et al. (2013). Stabilization of atherosclerotic plaques: an update. European Heart Journal, 34(42), 3251–3258.
pubmed: 23966311
Stone, G. W., et al. (2011). A prospective natural-history study of coronary atherosclerosis. The New England Journal of Medicine, 364(3), 226–235.
pubmed: 21247313
Naghavi, M., et al. (2003). From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part II. Circulation, 108(15), 1772–1778.
pubmed: 14557340
Arbab-Zadeh, A., & Fuster, V. (2015). The myth of the “vulnerable plaque”: transitioning from a focus on individual lesions to atherosclerotic disease burden for coronary artery disease risk assessment. Journal of the American College of Cardiology, 65(8), 846–855.
pubmed: 25601032 pmcid: 4344871
Chiu, B., et al. (2011). Fast plaque burden assessment of the femoral artery using 3D black-blood MRI and automated segmentation. Medical Physics, 38(10), 5370–5384.
pubmed: 21992357 pmcid: 3189974
Kantor, B., et al. (2009). Coronary computed tomography and magnetic resonance imaging. Current Problems in Cardiology, 34(4), 145–217.
pubmed: 19269527 pmcid: 2709495
Vaidya, K., et al. (2018). Colchicine therapy and plaque stabilization in patients with acute coronary syndrome: a CT coronary angiography study. JACC: Cardiovascular Imaging, 11(2 Pt 2), 305–316.
pubmed: 29055633
Bauriedel, G., et al. (1994). Colchicine antagonizes the activity of human smooth muscle cells cultivated from arteriosclerotic lesions after atherectomy. Coronary Artery Disease, 5(6), 531–539.
pubmed: 7952413
Tatsumi, M., et al. (2003). Fluorodeoxyglucose uptake in the aortic wall at PET/CT: possible finding for active atherosclerosis. Radiology, 229(3), 831–837.
pubmed: 14593193 pmcid: 14593193
Tawakol, A., et al. (2005). Noninvasive in vivo measurement of vascular inflammation with F-18 fluorodeoxyglucose positron emission tomography. Journal of Nuclear Cardiology, 12(3), 294–301.
pubmed: 15944534
Ishii, H., et al. (2010). Comparison of atorvastatin 5 and 20 mg/d for reducing F-18 fluorodeoxyglucose uptake in atherosclerotic plaques on positron emission tomography/computed tomography: a randomized, investigator-blinded, open-label, 6-month study in Japanese adults scheduled for percutaneous coronary intervention. Clinical Therapeutics, 32(14), 2337–2347.
pubmed: 21353104
Vucic, E., et al. (2011). Pioglitazone modulates vascular inflammation in atherosclerotic rabbits noninvasive assessment with FDG-PET-CT and dynamic contrast-enhanced MR imaging. JACC: Cardiovascular Imaging, 4(10), 1100–1109.
pubmed: 21999870
Martinez, G. J., Celermajer, D. S., & Patel, S. (2018). The NLRP3 inflammasome and the emerging role of colchicine to inhibit atherosclerosis-associated inflammation. Atherosclerosis, 269, 262–271.
pubmed: 29352570
Martinez, G. J., et al. (2015). Colchicine acutely suppresses local cardiac production of inflammatory cytokines in patients with an acute coronary syndrome. Journal of the American Heart Association, 4(8), e002128.
pubmed: 26304941 pmcid: 4599469
Yabushita, H., et al. (2002). Characterization of human atherosclerosis by optical coherence tomography. Circulation, 106(13), 1640–1645.
pubmed: 12270856
Rodriguez-Granillo, G. A., et al. (2005). New insights towards catheter-based identification of vulnerable plaque. Revista Española de Cardiología, 58(10), 1197–1206.
pubmed: 16238988
Puri, R., et al. (2015). Impact of statins on serial coronary calcification during atheroma progression and regression. Journal of the American College of Cardiology, 65(13), 1273–1282.
pubmed: 25835438
Kaminiotis, V. V., et al. (2017). Per os colchicine administration in cholesterol fed rabbits: triglycerides lowering effects without affecting atherosclerosis progress. Lipids in Health and Disease, 16(1), 184.
pubmed: 28950870 pmcid: 5615463
Wojcicki, J., et al. (1986). The effect of colchicine on the development of experimental atherosclerosis in rabbits. Polish Journal of Pharmacology and Pharmacy, 38(4), 343–348.
pubmed: 3774628
Brooks, P. M., Burton, D., & Forrest, M. J. (1987). Crystal-induced inflammation in the rat subcutaneous air-pouch. British Journal of Pharmacology, 90(2), 413–419.
pubmed: 3030485 pmcid: 1916951
Maduri, S., & Atla, V. R. (2012). Formulation of colchicine ointment for the treatment of acute gout. Singapore Medical Journal, 53(11), 750–754.
pubmed: 23192503
Marcovici, I., et al. (1993). Colchicine and post-inflammatory adhesions in a rabbit model: a dose-response study. Obstetrics and Gynecology, 82(2), 216–218.
pubmed: 8336867
Angelidis, C., et al. (2018). Colchicine pharmacokinetics and mechanism of action. Current Pharmaceutical Design, 24(6), 659–663.
pubmed: 29359661

Auteurs

Alberto Cecconi (A)

Centro Nacional de Investigaciones Cardiovasculares (CNIC), Calle de Melchor Fernández Almagro, 3, 28029, Madrid, Spain.
Servicio de Cardiología, Hospital Universitario de La Princesa, Madrid, Spain.

Jean Paul Vilchez-Tschischke (JP)

Centro Nacional de Investigaciones Cardiovasculares (CNIC), Calle de Melchor Fernández Almagro, 3, 28029, Madrid, Spain.
Servicio de Cardiología, Complejo hospitalario Ruber Juan Bravo, Madrid, Spain.

Jesus Mateo (J)

Centro Nacional de Investigaciones Cardiovasculares (CNIC), Calle de Melchor Fernández Almagro, 3, 28029, Madrid, Spain.

Javier Sanchez-Gonzalez (J)

Philips Healthcare, Madrid, Spain.

Samuel España (S)

Centro Nacional de Investigaciones Cardiovasculares (CNIC), Calle de Melchor Fernández Almagro, 3, 28029, Madrid, Spain.

Rodrigo Fernandez-Jimenez (R)

Centro Nacional de Investigaciones Cardiovasculares (CNIC), Calle de Melchor Fernández Almagro, 3, 28029, Madrid, Spain.
The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, USA.
CIBER de Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain.

Beatriz Lopez-Melgar (B)

Centro Nacional de Investigaciones Cardiovasculares (CNIC), Calle de Melchor Fernández Almagro, 3, 28029, Madrid, Spain.
CIBER de Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain.
Servicio de Cardiología, Hospital Universitario HM Puerta del Sur, Móstoles, Spain.

Leticia Fernández Friera (L)

Centro Nacional de Investigaciones Cardiovasculares (CNIC), Calle de Melchor Fernández Almagro, 3, 28029, Madrid, Spain.
CIBER de Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain.
HM Hospitales - Centro Integral de Enfermedades Cardiovasculares HM-CIEC, Madrid, Spain.

Gonzalo J López-Martín (GJ)

Centro Nacional de Investigaciones Cardiovasculares (CNIC), Calle de Melchor Fernández Almagro, 3, 28029, Madrid, Spain.

Valentin Fuster (V)

Centro Nacional de Investigaciones Cardiovasculares (CNIC), Calle de Melchor Fernández Almagro, 3, 28029, Madrid, Spain.
The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, USA.

Jesus Ruiz-Cabello (J)

CIC biomaGUNE, 20014, Donostia-San Sebastián, Spain.
IKERBASQUE, Basque Foundation for Science, Bilbao, Spain.
CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain.
Universidad Complutense Madrid, Madrid, Spain.

Borja Ibañez (B)

Centro Nacional de Investigaciones Cardiovasculares (CNIC), Calle de Melchor Fernández Almagro, 3, 28029, Madrid, Spain. bibanez@cnic.es.
CIBER de Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain. bibanez@cnic.es.
Servicio de Cardiología, IIS - Fundación Jiménez Díaz Hospital, Madrid, Spain. bibanez@cnic.es.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH